Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases
Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases
复制标题
DOI：
10.1007/s11060-004-4536-3
复制
发表时间：
2005-01-01
影响因子：
3.9
通讯作者：
Musset, L
中科院分区：
文献类型：
--
作者：
Aguirre-Cruz, L;Charuel, JL;Musset, L
大约一半的副肿瘤性疾病患者会对肿瘤和神经系统表达的神经元抗原产生免疫反应。在31例抗-Hu抗体和19例抗-Yo抗体患者中，我们寻找了额外的非神经元自身抗体的存在，并进一步研究了这种自身抗体的存在是否与特定的肿瘤学或神经学表现相关。48%的抗Hu抗体阳性患者抗核抗体（ANA）滴度≥ 1：40，37%的抗Yo抗体阳性患者ANA滴度≥ 1：40。42%的抗Yo抗体阳性患者同时存在抗胞浆抗体。非神经元自身抗体的存在与患者的临床特征之间没有特定的相关性。特别是，无论是潜在癌症的类型，总生存期，肿瘤治疗反应，也没有神经系统的表现与血清学状态。
About half of the patients with paraneoplastic diseases develop an immune response against neuronal antigens expressed by both the tumor and the nervous system. In 31 patients with anti-Hu antibodies and 19 patients with anti-Yo antibodies, we searched for the presence of additional non-neuronal auto-antibodies and further studied whether the presence of such auto-antibodies was correlated with a specific oncological or neurological presentation. Positive antinuclear antibodies (ANA) were found at a titer of 1:40 or above in 48% patients with anti-Hu antibodies, and in 37% patients with anti-Yo antibodies. Anti-cytoplasmic antibodies were also detected in 42% patients with anti-Yo antibodies. No specific correlation between the presence of non-neuronal auto-antibodies and clinical characteristics of the patients could be identified. In particular, neither the type of underlying cancer, the overall survival, the tumor response to treatment, nor the neurological presentation were related to the serological status.